Amryt Pharma (Amryt Pharma) Operating Income : $-45.1 Mil (TTM As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Operating Income?

Amryt Pharma's Operating Income for the three months ended in Sep. 2022 was $-10.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 was $-45.1 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Amryt Pharma's Operating Income for the three months ended in Sep. 2022 was $-10.5 Mil. Amryt Pharma's Revenue for the three months ended in Sep. 2022 was $61.1 Mil. Therefore, Amryt Pharma's Operating Margin % for the quarter that ended in Sep. 2022 was -17.11%.

Good Sign:

Amryt Pharma PLC operating margin is expanding. Margin expansion is usually a good sign.

Amryt Pharma's 5-Year average Growth Rate for Operating Margin % was 49.80% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Amryt Pharma's annualized ROC % for the quarter that ended in Sep. 2022 was -9.01%. Amryt Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -298.15%.

Amryt Pharma Operating Income Historical Data

The historical data trend for Amryt Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Operating Income Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Operating Income

Get a 7-Day Free Trial

-17.04

-18.04

-32.78

-45.44

-21.64

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Operating Income	Get a 7-Day Free Trial															-10.14	-15.62	-12.38	-6.61	-10.46

Amryt Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.1 Mil.

Amryt Pharma (NAS:AMYT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Amryt Pharma's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-41.84 * ( 1 - -14.89% )	/	( (546.252	+	520.624)	/ 2 )
=	-48.069976	/	533.438
=	-9.01 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	764.744	-	127.909	-	( 90.583	-	max(0, 151.028	-	265.345	+	90.583	))
=	546.252

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	736.875	-	134.947	-	( 83.25	-	max(0, 143.144	-	224.448	+	83.25	))
=	520.624

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Amryt Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-46.976	/	( ( (7.109 + max(17.665, 0))	+	(6.738 + max(-14.186, 0)) )	/	2 )
=	-46.976	/	( ( 24.774	+	6.738 )	/	2 )
=	-46.976	/	15.756
=	-298.15 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(37.729	+	124.185	+	0.15000000000003)	-	(127.909	+	0	+	16.49)
=	17.665

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(37.604	+	90.238	+	0.15000000000001)	-	(134.947	+	0	+	7.231)
=	-14.186

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Amryt Pharma's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	-10.46	/	61.126
	=	-17.11 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Amryt Pharma Operating Income Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).